Last $1.31 USD
Change Today +0.02 / 1.55%
Volume 248.8K
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

durect corporation (DRRX) Snapshot

Open
$1.28
Previous Close
$1.29
Day High
$1.31
Day Low
$1.26
52 Week High
02/7/14 - $2.69
52 Week Low
06/5/13 - $0.76
Market Cap
144.7M
Average Volume 10 Days
310.6K
EPS TTM
$-0.21
Shares Outstanding
110.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DURECT CORPORATION (DRRX)

durect corporation (DRRX) Related Businessweek News

No Related Businessweek News Found

durect corporation (DRRX) Details

DURECT Corporation, a specialty pharmaceutical company, is engaged in the development of pharmaceutical products based on its proprietary drug delivery technology platforms in the United States and internationally. It focuses on the development of various products for the treatment of various chronic and episodic disease areas, such as pain, central nervous system disorders, metabolic disorders, cardiovascular disease, and other chronic diseases. The company’s products comprise ALZET product line that consists of osmotic pumps and accessories, which are used for experimental research in mice, rats, and other laboratory animals; and a range of standard and custom biodegradable polymers that are used as raw materials in the pharmaceutical and medical devices under the brand name of LACTEL. Its products also include REMOXY, an oral oxycodone gelatin capsule for chronic pain; POSIDUR, a formulation of bupivacaine for the treatment of post-surgical pain that has completed Phase III clinical study; ELADUR, a Phase II transdermal bupivacaine patch intended to provide delivery of bupivacaine; and TRANSDUR-Sufentanil that has completed Phase II transdermal sufentanil patch, which is intended to provide delivery of sufentanil. In addition, the company’s products pipeline comprises ORADUR-based opioids, including hydrocodone and hydromorphone that are in Phase I clinical trials for the treatment of pain; oxymorphone, an ORADUR-based opioid for which IND has been accepted by the FDA; ORADUR-ADHD, a drug candidate in Phase I clinical trial for the treatment of attention deficit hyperactivity disorder; and Relday, an injectable risperidone product in Phase I clinical trial used to treat the symptoms of schizophrenia and bipolar I disorder. It has strategic agreements with various companies, such as Pain Therapeutics, Inc.; Pfizer Inc.; Zogenix, Inc.; Hospira, Inc.; and Nycomed Danmark ApS. The company was founded in 1998 and is headquartered in Cupertino, California.

101 Employees
Last Reported Date: 02/28/14
Founded in 1998

durect corporation (DRRX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $454.9K
Co-Founder, Chairman and Chief Scientific Off...
Total Annual Compensation: $269.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $301.3K
Executive Vice President of Pharmaceutical Sy...
Total Annual Compensation: $293.6K
Compensation as of Fiscal Year 2012.

durect corporation (DRRX) Key Developments

DURECT Corporation Promotes Judy Joice from Vice President, Operations and Corporate Quality Assurance to Senior Vice President, Operations and Corporate Quality Assurance

On March 28, 2014, the board of directors of DURECT Corporation promoted Judy Joice, from Vice President, Operations and Corporate Quality Assurance to Senior Vice President, Operations and Corporate Quality Assurance, effective immediately. Ms. Joice joined the Company in 2007 as Executive Director, Quality Assurance, and has over 25 years of experience in the pharmaceutical industry with such companies as Nektar Therapeutics, Oread and Syntex Research.

DURECT Corporation Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

DURECT Corporation reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported total revenues of $4.289 million compared to $3.262 million for the same period a year ago. Loss from operations was $5.092 million compared to $5.591 million for the same period a year ago. Net loss was $5.1 million or $0.05 per diluted share compared to $5.498 million or $0.06 per diluted share for the same period a year ago. For the year, the company reported total revenues of $15.326 million compared to $53.070 million for the same period a year ago. Loss from operations was $21.162 million compared to income of $16.056 million for the same period a year ago. Net loss was $21.452 million or $0.21 per diluted share compared to net income of $16.2 million or $0.18 per diluted share for the same period a year ago. Excluding the accelerated recognition of deferred revenue, DURECT's reported revenues would have been $17.7 million for the year ended December 31, 2012 and reported net loss would have been $19.2 million for the year ended December 31, 2012.

DURECT Corporation to Report Q4, 2013 Results on Feb 27, 2014

DURECT Corporation announced that they will report Q4, 2013 results at 9:05 PM, GMT Standard Time on Feb 27, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRRX:US $1.31 USD +0.02

DRRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Acura Pharmaceuticals Inc $1.30 USD +0.015
Alexza Pharmaceuticals Inc $4.13 USD +0.03
Cumberland Pharmaceuticals Inc $4.46 USD -0.06
Elite Pharmaceuticals Inc $0.34 USD +0.0028
Flamel Technologies SA $11.26 USD +0.66
View Industry Companies
 

Industry Analysis

DRRX

Industry Average

Valuation DRRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.1x
Price/Book 4.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DURECT CORPORATION, please visit www.durect.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.